Prime Medicine (PRME) Research & Development (2021 - 2026)
Prime Medicine (PRME) posted Research & Development of $34.1 million for Q1 2026, down 1.74% on a QoQ basis from $34.7 million in Q4 2025, and down 15.92% year-over-year from $40.6 million in Q1 2025.
Prime Medicine (PRME) Research & Development (2021 - 2026) Analysis & Trends
Prime Medicine's Research & Development history runs 6 years deep, the most recent figure standing at $34.1 million for Q1 2026.
- Quarterly Research & Development fell 15.92% year-over-year to $34.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $154.2 million (down 2.47% YoY) and the FY2025 annual result came in at $160.6 million, up 3.44% from the prior year.
- Research & Development was $34.1 million for Q1 2026 at Prime Medicine, down from $34.7 million in the prior quarter.
- Across five years, Research & Development topped out at $44.0 million in Q3 2025 and bottomed at $13.7 million in Q1 2022.
- A 5-year average of $34.4 million and a median of $34.7 million in 2025 frame the typical range for Research & Development.
- Peak annual rise in Research & Development reached 238.47% in 2022, while the deepest fall reached 45.05% in 2022.
- Prime Medicine's Research & Development stood at $29.1 million in 2022, then soared by 42.66% to $41.5 million in 2023, then fell by 17.74% to $34.1 million in 2024, then gained by 1.77% to $34.7 million in 2025, then fell by 1.74% to $34.1 million in 2026.
- Business Quant data shows PRME's Research & Development at $34.1 million in Q1 2026, $34.7 million in Q4 2025, and $44.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 1.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 541.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | -443.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 343.97 Mn |
| 10 | Prime Medicine | 524.20 Mn | 524.20 Mn | - | 34.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 34.11 Mn |
| Dec 31, 2025 | 34.71 Mn |
| Sep 30, 2025 | 43.99 Mn |
| Jun 30, 2025 | 41.38 Mn |
| Mar 31, 2025 | 40.56 Mn |
| Dec 31, 2024 | 34.10 Mn |
| Sep 30, 2024 | 40.34 Mn |
| Jun 30, 2024 | 43.07 Mn |
| Mar 31, 2024 | 37.77 Mn |
| Dec 31, 2023 | 41.46 Mn |
| Sep 30, 2023 | 40.97 Mn |
| Jun 30, 2023 | 34.60 Mn |
| Mar 31, 2023 | 30.88 Mn |
| Dec 31, 2022 | 29.06 Mn |
| Sep 30, 2022 | 25.05 Mn |
| Jun 30, 2022 | 18.94 Mn |
| Mar 31, 2022 | 13.68 Mn |
| Dec 31, 2021 | 52.89 Mn |
| Sep 30, 2021 | 7.40 Mn |